Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-14 · accession 0001864159-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-14 | 2025-11-14 | JANX | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $30.00 | -3,333 | 85.0K | -4% | -$100.0K |
| D | 2025-11-14 | 2025-11-14 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $10.59 | +3,333 | 88.3K | +4% | +$35.3K |
| D | 2025-11-14 | 2025-11-14 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $0.00 | -3,333 | 118.1K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-14 | S | D | 3,333 | $30.00 | 84,974 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-14 | M | A | 3,333 | $10.59 | 88,307 | D | — | — | (F1) Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025. |
| 3 | Derivative | Stock Option (right to buy) | 2025-11-14 | M | D | 3,333 | $0.00 | 118,101 | D | $10.59 · — to 2031-05-13 | 3,333 Common Stock | (F3) Immediately exercisable. |